Targeted Therapy for MPNs: Going Beyond JAK Inhibitors

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• JAK inhibition effectively manages myeloproliferative neoplasms (MPNs) symptoms and splenomegaly.
• Long-term JAK inhibitor treatment often leads to disease progression in MPNs patients.
• Current JAK inhibitors have limited anti-clonal effects and do not prevent progression to the blast phase.

Purpose of the Study:

• To review novel targeted agents beyond JAK inhibitors for MPNs.
• To investigate these agents in both chronic and accelerated/blast phases of MPNs.
• To explore therapies that may alter the natural history of MPNs.

Main Methods:

• Review of prospective data for novel targeted agents in MPNs.
• Summary of ongoing phase III clinical trials involving these agents.
• Focus on agents like BET, BCL, LSD1, PI3K, IDH, telomerase, and MDM2 inhibitors.

Main Results:

• Several novel targeted therapies are under investigation as monotherapy or in combination with JAK inhibitors.
• These agents show promise in reducing MPNs symptom burden.
• Data from ongoing trials suggest potential to impact disease progression.

Conclusions:

• Novel targeted therapies offer a promising alternative and adjunct to JAK inhibitors in MPNs.
• These agents may provide a greater anti-clonal effect and potentially alter the natural course of MPNs.
• Further research and clinical trials are crucial to establish the efficacy and safety of these novel agents.